MPN in youth: studying disease features and complications
Part of Blood & lymphatic clinical trials.
This study looks at young people (children, teens, and adults under 30) who have a type of blood cancer called myeloproliferative neoplasm (MPN). It aims to better understand the disease and its complications over time, with the goal of improving care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with a myeloproliferative neoplasm (MPN) like polycythemia vera, essential thrombocythemia, or myelofibrosis before age 30.
- You must sign a consent form to join the FIMBANK project, which stores blood and tissue for research.
- You agree to be part of this VYP study.
- You are 18 years or older when joining the study.
- You are covered by a social security (health insurance) plan.
- You are not under legal guardianship or curatorship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a type of white blood cell (monocyte) affects myeloproliferative neoplasms, a group of blood cancers. It aims to help doctors better understand these diseases and improve treatment.
This study is a “registry,” meaning it collects information about adults with specific types of myeloproliferative neoplasms (MPNs). It helps researchers better understand these diseases and may improve future care.
This study looks at immune cells (monocytes) in people with certain blood cancers. Researchers want to understand how these cells behave and change over time. You can join if you are newly diagnosed and haven't started treatment yet.
This study looks at how 'epigenetic age' (a measure of certain changes in your DNA) relates to the way blood cancers called myeloproliferative neoplasms (MPNs) develop and progress. It may help doctors better understand and predict the course of these diseases.
This study looks at the genetic changes that happen when a myeloproliferative neoplasm (a blood cancer that grows slowly) turns into acute myeloid leukemia (a more aggressive leukemia). By studying your bone marrow samples, researchers hope to find new ways to target and treat this type of leukemia.
This study looks at how a medicine called pegylated interferon affects “myeloproliferative neoplasms” (MPNs), a group of slow-growing blood cancers. You may be included whether your MPN is newly diagnosed or already being treated, mainly to help researchers understand the treatment’s effects.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.